This week we interviewed Brennan Marilla. Brennan has a 30-year track record of driving growth and commercializing transformative therapies in med-tech. He currently serves as Chief Commercial & Operating Officer for Israeli start-up OSSIO, where he has helped build one of the fastest growing, disruptive companies in the orthopedic implant market over the last 6 years.

Before OSSIO, he was Chief Commercial Officer for Surgical Specialties Corp (now Corza Medical), where significant improvements in top and bottom-line performance for the contract manufacturer led to a successful acquisition by Vivo Capital in 2017. Prior, he was VP & GM of Covidien’s $650M Endovascular business and VP, Sales and Marketing for their $1B+ Peripheral Vascular sector. In his tenure, these franchises rapidly transformed into a market-leading brand through multiple product introductions, disruptive technology acquisitions, and market development campaigns.   

Before Covidien, he spent 12 years at Medtronic where he was VP, US Sales and Director, Global Marketing for their aortic stent graft business, where he helped develop these therapies into what is now the standard of care in a $2 billion global market.